GLP-1 Competitive Market — June 26, 2026
|
Lilly’s July 1 Medicare GLP-1 Bridge hands Part D’s ~51 million beneficiaries access to both Foundayo and Zepbound — a structural payer opening Novo Nordisk has no comparable mechanism to match, just as Lilly steers Foundayo’s European launch into telehealth to sidestep Most Favored Nation reference pricing.
Today’s top developments:
|
What to Watch
- Novo’s Medicare counter-move — Watch for Novo Nordisk to announce a Medicare Part D access program for Wegovy by Q3 2026; Lilly’s July 1 bridge creates competitive urgency Novo cannot ignore without surrendering the 65-plus obesity cohort.
- Retatrutide Phase 3 readout — The single most consequential catalyst in the GLP-1 pipeline; a confirmed 20-plus percent weight loss result would force Amgen, Novo, and Roche to reprice their entire obesity development strategies.
- Ramadan-fasting dosing race — Lilly’s orforglipron fasting study signals a Southeast Asia and Middle East market strategy; expect competitive filings from Novo addressing the same dosing-flexibility gap for oral semaglutide within 12 months.
- 340B reform pressure — Senator Cassidy’s 340B reform push, if it advances, would compress safety-net channel margins for all GLP-1 manufacturers and could become a formulary access flashpoint in Q4 2026 budget negotiations.
This brief highlights the edition’s top stories. Read the full June 26, 2026 edition → for all stories and analysis — or browse the GLP-1 Competitive Market archive.